… We did a longitudinal study of patients who had recovered from COVID-19 up to day 180
post-symptom onset by monitoring changes in neutralising antibody levels using a previously …

… study, using either live SARS-CoV-2 particles or retroviruses pseudotyped with the SARS-CoV-2
S viral surface protein (Spike), we studied … from a cohort of 140 SARS-CoV-2 qPCR-…

Background The relationship of host immune response and viral replication with health
outcomes in patients with COVID-19 remains to be defined. We aimed to characterize the …

… We used two different immunoassays to study the kinetics of SARS-CoV-2-specific antibodies
(IgM, IgA, and IgG) for 6 weeks after the onset of symptoms (fever) in adult patients with …

Objective Currently, little is known about the progression of an immune response against
SARSCoV- 2 upon infection or sub-infection-exposure over time. We examined the serologic …

… This study shows the persistence of several SARS-CoV-2 antigen-specific antibodies 6
months following COVID-19. It shows that almost all patients with mild COVID-19 retain …

… Furthermore, our longitudinal study showed that the magnitude and duration of the antibody
response against SARS-CoV-2 is heterogeneous and varies widely between individuals (5, …

… nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating
in a population-based longitudinal study … participants who were SARS-CoV-2 seropositive …

… Our results support previous studies that have found increased risk of SARS-CoV-2
seropositivity for healthcare workers [3, 4, 12], people of Asian ethnicity [3, 5, 12] and people with …

… longitudinal study to use patient-reported information linked to real-world data through the
Innovative Support for Patients With SARS-COV2 … In this study, researchers follow a sample of …